We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
The Eversense® 365 Sensor Kit includes:
The Eversense® 365 Smart Transmitter Kit includes:
The system is indicated (approved) for use to replace fingerstick blood glucose measurements for diabetes treatment decisions.
Pay close attention to your glucose values, symptoms, and trends. If your symptoms are different than the sensor glucose values or what the alert indicates, confirm your glucose value with a blood glucose meter test before making a treatment decision.*
To make a treatment decision, the user should consider:
When to NOT make a treatment decision:

* If you have any uncertainly in how or when to make treatment decisions, always speak with your healthcare professional.
Note: Always refer to the glucose information on your Eversense 365 App on your smartphone to make treatment decisions. Do not use a secondary display like the Apple Watch or Eversense NOW App.
A blood glucose meter is required for calibrating the CGM System, and to make treatment decisions under certain conditions. See Understanding Treatment Decisions with CGM in the Eversense® 365 CGM User Guide for more information.
Calibration is used to ensure the accuracy of the CGM system.
The Eversense® 365 CGM System include the Eversense 365 Sensor. In the ENHANCE Clinical Trial the MARD for the Eversense® 365 sensor was 8.8%.
For more details on the results of the clinical study, refer to the Eversense® 365 User Guide. The User Guide is available for download at www.eversensecgm.com/user-guides/
The proximity of the Eversense® 365 Sensor with medicated patches has not been studied. Please contact your health care professional for advisement.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
MKT-001692 Rev 1